This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Ascendis Pharma Growth Disorders A/s. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: Felix Cleenmann: Innovator in Controlled-Release CNP Agonists
Introduction
Felix Cleenmann is a notable inventor based in Mainz, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of controlled-release CNP agonists. His innovative work has the potential to enhance treatment options for various medical conditions.
Latest Patents
Felix Cleenmann holds a patent for "Controlled-release CNP agonists with increased NEP stability." This invention relates to controlled-release CNP agonists that exhibit an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay compared to the corresponding released CNP agonist. The patent also covers pharmaceutical compositions comprising these controlled-release CNP agonists, their uses, and methods of treatment.
Career Highlights
Felix is currently associated with Ascendis Pharma Growth Disorders A/S, where he continues to advance his research and development efforts. His work is instrumental in the pharmaceutical industry, particularly in addressing growth disorders through innovative therapeutic solutions.
Collaborations
Felix has collaborated with notable colleagues, including Kennett Sprogøe and Harald Rau. Their combined expertise contributes to the success of their projects and the advancement of pharmaceutical innovations.
Conclusion
Felix Cleenmann's contributions to the field of controlled-release CNP agonists exemplify the impact of innovative thinking in pharmaceuticals. His work not only enhances treatment options but also showcases the importance of collaboration in scientific advancements.